Advertisement

Neuroendokrine Tumoren des Gastrointestinaltraktes

  • M. Engelbach
  • J. Beyer

Zusammenfassung

Bereits im Jahre 1967 fasste Pearse Zellen unter dem Begriff APUD Zellsysteme zusammen (“amine and precursor uptake and decarboxylation”), die die Fähigkeit besitzen, aromatische Amine zu synthetisieren, Vorstufen der Amine aufzunehmen und Aminosäuren mittels eines Enzyms zu den entsprechenden Aminen zu decarboxylieren. Aufgrund der Beobachtung, dass die in diesen Zellen synthetisierten Peptidhormone auch im Zentralnervensystem von funktioneller Bedeutung sind und immunhistochemische Markerenzyme ebenfalls in bei den Zellsystemen nachweisbar sind, wurde der erweiterte Terminus des neuroendokrinen Systems eingeführt. Das diffuse neuroendokrine System umschließt hierbei die neuroendokrinen Zellen, die nicht in makroskopisch kompakten Organen zusammengelagert sind. Im Bereich des Gastrointestinaltraktes konnten mittlerweile 15 verschiedene Zelltypen des diffusen neuro endokrinen Systems sowie eine Reihe der von ihnen produzierten Hormone identifiziert werden.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

Literatur zu Abschn. 14.1

  1. Green D.W., Gomez G., Greeley G.H. Jr (1989) Gastrointestinal peptides. Gastroenterol Clin North Am 18(4):695–733PubMedGoogle Scholar
  2. Modlin I.M., Basson M.D. (1993) Clinical applications of gastrointestinal hormones. Endocrinol Metab Clin North Am 22(4):823–844PubMedGoogle Scholar
  3. Solcia E., Fiocca R., Rindi G., Villani L., Cornaggia M., Capella C. (1993) The pathology of the gastrointestinal endocrine system. Endocrinol Metab Clin North Am 22(4):795–821PubMedGoogle Scholar

Literatur zu Abschn. 14.2

  1. Ahlman H., Wangberg B., Nilsson O. (1993) Growth regulation in carcinoid tumors. Endocrinol Metab Clin North Am 22(4):889–915PubMedGoogle Scholar
  2. Arnold R., Benning R., Neuhaus C., Rolwage M., Trautmann M.E. (1993) Gastroenteropancreatic endocrine tumours: effect of Sandostatin on tumour growth. The German Sandostatin Study Group. Digestion 54(Suppl 1): 72–75PubMedCrossRefGoogle Scholar
  3. Arnold R., Trautmann M.E., Creutzfeldt W. et al. (1996) Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 38(3):430–438PubMedCrossRefGoogle Scholar
  4. Bukowsky R.M., Johnson K.G., Peterson R.F., Stephens R.L., Rivkin S.E., Neilan B., Constanzi J.H. (1987) A phase II trail of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study. Cancer 60(12):2891–2895CrossRefGoogle Scholar
  5. Bukowski R.M., Stephens R., Oishi N. (1983) Phase II trial of 5-FU.Adriamycin, cyclophosphamide, and streptozotocin in metastatic carcinoid. Proc Am Soc Clin Oncol 2: 130Google Scholar
  6. Burkowsky R.M., Tangen C.M., Peterson R.F. et al. (1994) Phase II trial of dimethyltriazenoimidazole carboxiamide in patients with metastatic carcinoid. A Southwest Oncology Group Study. Cancer 73(5):1505–1508CrossRefGoogle Scholar
  7. Caplin M.E., Buscombe J.R., Hilson A.J., Jones A.L., Watkinson A.F., Burroughs A.K. (1989) Carcinoid tumor. Lancet 352(9130):799–805Google Scholar
  8. Casper E.S., Mittelman A., Kelson D., Young C.W. (1982) Phase I clinical trial of tludarabine phosphate (F-ara-AMP). Cancer Chemother Pharmacol 15(3):233–235Google Scholar
  9. Clouse M.E., Perry L., Stuart K., Stokes K.R. (1994) Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Digestion 55(Suppl 3):92–97PubMedCrossRefGoogle Scholar
  10. Creutzfeldt W. (1994) Historical background and natural history of carcinoids. Digestion 55(Suppl 3):3–10PubMedCrossRefGoogle Scholar
  11. di Bartolomeo M., Bajetta E., Buzzoni R. et al. (1996) Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 77(2):402–408PubMedCrossRefGoogle Scholar
  12. Godwin J.D. (1975) Carcinoid tumors: an analysis of 2837 cases. Cancer 36: 560–569PubMedCrossRefGoogle Scholar
  13. Frank M., Klose K.I., Wied M., Ishaque N., Schade-Brittinger C., Arnold R. (1999) Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 94(5):1381–1387PubMedGoogle Scholar
  14. Janson E.T., Ronnblom L., Ahlstrom H., Grander D., Alm G., Einhorn S., Oberg K. (1992) Treatment with alpha-interferon versus Alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial. Ann Oncol 3(8):635–638PubMedGoogle Scholar
  15. Kelsen D.P., Cheng E., Kemeny N. (1982) Streptozotocin and adriamycin in the treatment of apud tumors. Proc Am Assoc Cancer Res 23: 433Google Scholar
  16. Lamberts S.W., van der Lely A.J., de Herder W.W., Hotland L.J. (1996) Octreotide. N Engl J Med 334(4):246–254PubMedCrossRefGoogle Scholar
  17. Moertel C.G., Hanley J.A. (1979) Combination chemotherapy trails in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 2(4):327–334PubMedGoogle Scholar
  18. Moertel C.G., Hanley J.A., Johnson L.A.N. (1980) Streptozocin alone compared with streptozocin plus flourouracil in the treatment of advanced islet-cell carcinoma. Engl J Med 303(21):1189–1194CrossRefGoogle Scholar
  19. Moertel C.G., Kvols L.K., O’Connell M.J., Rubin J. (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68(2):227–232PubMedCrossRefGoogle Scholar
  20. Neijt J.P., Lacave A.J., Splinter T.A., Taal B.G., Veenhof C.H., Sahmoud T., Lips C.J. (1995) Mitoxantrone in metastatic apudomas: a phase II study of the EORTC Gastro-Intestinal Cancer Cooperation Group. Br J Cancer 71(1):106–108PubMedCrossRefGoogle Scholar
  21. Newton J.N., Swerdlow A.J., dos Santos Silva I.M., Vessey M.P., Grahame Smith D.G., Primatesta P., Reynolds D.J. (1994) The epidemiology of carcinoid tumours in England and Scotland. Br J Cancer 70(5):939 942Google Scholar
  22. Norheim I., Öberg K., Theodorsson Norheim E et al. (1987) Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg 206(2):115–125Google Scholar
  23. Oberg K. (1994) Treatment of neuroendocrine tumors. Cancer Treat Rev 20: 331–355PubMedCrossRefGoogle Scholar
  24. Olney J.R., Urdaneta L.F., Al Jurf A.S., Jochimsen P.R., Shirazi S.S. (1985) Carcinoid tumors of the gastrointestinal tract. Am Surg 51(1):37–41PubMedGoogle Scholar
  25. Otte A., Mueller-Brand J., Dellas S., Nitzsche E.U., Herrmann R., Maecke H.R. (1998) Yttrium-90-labelled somatostatinanalogue for cancer treatment (letter). Lancet 51(9100):417–418CrossRefGoogle Scholar
  26. Pearse A.G.E. (1967) The cytochemistry and ultrastructure of polypeptide hormone producing cells of the APUD series and the embryologic, histologic cells of the APUD se ries and the embryologic, histologic and pathologic implications of the concept. J Histochem Cytochem 17: 303–313CrossRefGoogle Scholar
  27. Roggo A., Wood W.C., Ottinger L.W. (1993) Carcinoid tumors of the appendix. Ann Surg 217(4):385–390PubMedCrossRefGoogle Scholar
  28. Rothmund M., Stinner B., Arnold R. (1991) Endocrine pancreatic carcinoma. Eur J Surg Oncol 17(2):191–199PubMedGoogle Scholar
  29. Rubin J., Ajani J., Schirmer W. et al. (1999) Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 17(2):600–606PubMedGoogle Scholar
  30. Sanders C. (1970) Autopsy report. Tex Rep Biol Med 28(3):177–178PubMedGoogle Scholar
  31. Shaw P.A. (1990) Carcinoid tumours of the appendix are different. J Pathol 162(3):189–190PubMedCrossRefGoogle Scholar
  32. Saltz L., Lauwers G., Wiseberg J., Kelsen D. (1993) A phase II trial of carboplatin in patients with advanced APUD tumors. Cancer 72(2):619–622PubMedCrossRefGoogle Scholar
  33. Saltz L., Kemeny N., Schwartz G., Kelsen D. (1994) A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors. Cancer 74(3):958–961PubMedCrossRefGoogle Scholar
  34. Verner J., Morrison A.B. (1974) Endocrine pancreatic islet disease with diarrhea. Report of a case due to diffuse hyperplasia of nonbeta islet tissue with a review of 54 additional cases. Arch Intern Med 133(3):492–499PubMedCrossRefGoogle Scholar
  35. Ziegler R., Piekardt C.R., Willig R.P. (1993) Karzinoid. In: Deutsche Gesellschaft für Endokrinologie (Hrsg) Rationelle Diagnostik in der Endokrinologie. Thieme, Stuttgart, p 118Google Scholar

Literatur zu Abschn. 14.3

  1. Fishbeyn V.A., Norton J.A., Benya R.V., Pisegna J.R., Venzon D.J., Metz D.C., Jensen R.T. (1993) Assessment and predietion of long-term eure in patients with the Zollinger-Ellison syndrome: the best approach. Ann Intern Med 119(3):199–206PubMedCrossRefGoogle Scholar
  2. Kaplan E.L., Horvath K., Udekwu A., Straus F., Schark C., Ferguson D.J., Skinner D.B. (1990) Gastrinomas: a 42-year experience. World J Surg 14(3):365–375; discussion 375–376PubMedCrossRefGoogle Scholar
  3. Kvols L.K., Moertel C.G., O’Connell M.J., Schutt A.J., Rubin J., Hahn R.G. (1986) Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 315(11):663–666PubMedCrossRefGoogle Scholar
  4. Maton P.N., Gardner J.D., Jensen R.T. (1989) Diagnosis and management of Zollinger-Ellison syndrome. Endocrinol Metab Clin North Am 18(2): 519–543PubMedGoogle Scholar
  5. Moertel C.G. et al. (1992) Streptozotocin-doxorubicin, streptozotocin fluoro uracil, or chlorzotocin in the treatment of advanced islet cell carcinoma. New Engl J Med 326: 519–523PubMedCrossRefGoogle Scholar
  6. Pisegna J.R.; Slimak G.G.; Doppman J.L. et-al. (1993) An evaluation of human recombinant alpha interferon in patients with metastatie gastrinoma. Gastroenterology 105(4):1179–1183PubMedGoogle Scholar
  7. Ruszniewski P., Ramdani A., Cadiot G., Lehy T., Mignon M., Bonfils S. (1993) Long term treatment with octreotide in patients with the Zollinger Ellison syndrome. Eur J Clin Invest 23(5):296–301PubMedCrossRefGoogle Scholar
  8. von Schrenck T., Howard J.M., Doppman J.L. et-al. (1988) Prospective study of chemotherapy in patients with metastatic gastrin oma. Gastroenterology 94(6):1326–1334Google Scholar
  9. Wolfe M.M., Jensen R.T. (1987) Zollinger-Ellison syndrome. Current concepts in diagnosis and management. N Engl J Med 317(19):1200–1209PubMedCrossRefGoogle Scholar
  10. Zollinger R.M., Ellison E.H. (1955) Pimary peptic ulcerations of the jejunum associated with islet cell tumors of the pankreas. Ann Surg 142: 709–728PubMedCrossRefGoogle Scholar

Literatur zu Abschn. 14.4

  1. Bloom-S.R.; Polak-J.M. (1980) Glucagonomas, Vipomas and Somatostatinomas. Clin Endocrinol Metabol 9: 285–297CrossRefGoogle Scholar
  2. Bloom S.R., Polak J.M. (1987) Glucagonoma syndrome. Am J Med 82(5B):25–36PubMedCrossRefGoogle Scholar
  3. Moertel C.G., Lefkopoulo M., Lipsitz S., Hahn R.G., Klaassen D. (1992) Streptozotocin-doxorubicin, streptozotocin-fluorouracil, or chlorzotocin in the treatment of advanced islet cell carcinoma. New Engl J Med 326: 519–523PubMedCrossRefGoogle Scholar
  4. Rothmund M., Stinner B., Arnold R. (1991) Endocrine pancreatic carcinoma. Eur J Surg Oncol 17(2):191–199PubMedGoogle Scholar
  5. Stacpoole P.W. (1981) The glucagonoma syndrome: clinical features, diagnosis, and treatment. Endocr Rev 2(3):347–361PubMedCrossRefGoogle Scholar
  6. Wermers R.A., Fatourechi V., Wynne A.G., Kvols L.K., Lloyd R.V. (1996) The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine (Baltimore) 75(2):53–63CrossRefGoogle Scholar

Literatur zu Abschn. 14.5

  1. Grier J.F. (1995) WDHA (watery diarrhea, hypokalemia, achlorhydria) syndrome: clinical features, diagnosis, and treatment. South Med J 88(1):22–2PubMedCrossRefGoogle Scholar
  2. Kraenzlin M.E., Ch’ng J.L., Wood S.M., Carr D.H., Bloom S.R. (1985) Long-term treatment of a Vipoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology 88: 185–187PubMedGoogle Scholar
  3. Krejs G.J. (1987) Vipoma syndrome. Am J Med 82(5B):37–48PubMedCrossRefGoogle Scholar
  4. Lundstedt C., Linjawi T., Amin T. (1994) Liver Vipoma: report of two cases and literature review. Abdom Imaging 19(5):433–437PubMedCrossRefGoogle Scholar
  5. Mekhjian H.S.; O’Dorisio T.M. (1987) Vipoma syndrome. Semin Oncol 14(3):282–291PubMedGoogle Scholar

Literatur zu Abschn. 14.6

  1. O’Brien T.D., Chejfec G., Prinz R.A. (1993) Clinical features of duodenal somatostatinomas. Surgery 114(6):1144–1147PubMedGoogle Scholar
  2. Somers G., Pipeleers Marichal M., Gepts W., Pipeleers D. (1983) A case of duodenal somatostatinoma: diagnostic usefulness of calcium-pentagastrin test. Gastroenterology 85(5):1192–1198Google Scholar
  3. Taccagni G.L., Carlucci M., Sironi M., Cantaboni A., Di Carlo V. (1986) Duodenal somatostatinoma with psammoma bodies: an immunohistochemical and ultrastructural study. Am J Gastroenterol 81: 33–37PubMedGoogle Scholar
  4. Vinik A.I., Strodel W.E., Eckhauser F.E., Moattari A.R., Lloyd R. (1987) Somatostatinomas, PPomas, neurotensinomas. Semin Oncol 14(3):263–281PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • M. Engelbach
  • J. Beyer

There are no affiliations available

Personalised recommendations